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Use of Chromogenic Peptide Substrates in the Determination
of Clotting Factors IIo VII, IX and X in Normal Plasma and in
Plasma of Patients Treated with Oral Anticoagulants
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c Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
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Abstract. Spectrophotometric methods were used to assay the clotting factors II, VII, IX
and X in plasma of 33 subjectively healthy human donors and in plasma of 98 patients
receiving long-term oral anticoagulant herapy. In 33 normal subjects the interindividual
variations in the plasma activities of the clotting factors II, VII, IX.and X are respectively
12.2,21.4,11.0and 15.0o/o.Aftercorrect ionfortheassayvariat ionstheremainingbiological
variations are respectively 11.7, 21.2,9,'l and 14.80/0.
Plasma from 98 patients receiving long-term anticoagulant herapy was assayed with
'Thrombotest', a clotting test in whole blood introduced by Owren and in these plasmas the
activity of each of the vitamin K-dependent factors was assayed with spectrophotometric
methods. For the clotting factors iX and VIi, novel spectrophotometric methods were applied
and the plasma activities thus measured were compared to results obtained with factor IX and
VII clotting assays.
Chromogenic activities of the different factors were correlated among each other and with
l/Thrombotest values. When the therapeutic range for Thrombotest values is set between 5
and 12.50/o the corresponding therapeutic ranges for the activity of the factors II, VII, IX and
Xarerespect ively 12.6-36.1,27.0-52.3.23.149.3 and 18.9-36.20lo(expressedasapercent-
age of the activity in normal pool plasma). The chromogenic assays for the factors II. VIl, IX
and X provide the same information on the therapeutic state of the patients in respectively
86.7 .  78 .6 .  81 .6  and 89 .8  0 /o  o f  the  cases .
Finally we discuss the suitabilit_v of the diíïerent assays to monilor oral anticoaguiant
theraov.
a Á 1 van Dieijen-visser/van werscvBrombacher/RosingrHemker/van Dieijen
Introduction
For several clotting factors spectropho-
tometric assays. based on the spiitting of spe-
cific chromogenic substrales. have been in-
troduced [1-3]. Amidolytic cleavage of such
a substrate by an activated clotting fac-
tor results in the reiease of p-nitroaniline
which absorbs at 405 nm. Conditions can be
chosen such that the change in absorbance at
405 nm is proportional to the concentration
of the activated enzyme cleaving the s-vn-
thetic substrate. The chromogenic substrate
52337 is speciftc for factor Xa and is used in
this study in the chromogenic assays for the
factors IX, X and VIL The chromogenic sub-
strate chromozym TH, specific for throm-
bin, is used in the factor II chromogenic
assay.
Synthesis of the clotting factors iI' VII. IX
and X is vitamin K-dependent and activities
of these factors in plasma rapidly diminish
when oral anticoagulant drugs are adminis-
tered. Immediately after the start of oral anti-
coagulant therapy, plasma activities of the
four àctors start decreasing with velocities
depending on their haif-life in plasma. Factor
VII disappears most rapidly (TVz,4-6 h) [4],
hereafter factor IX (TYz, 18-30 h) [4, 5]. The
half-lives offactors X and II are about 40-60
and 48-96 h, respectively [4-6]' In patients
receiving long-term treatment with oral anli-
coagulants the ciotting activities of the four
viramin K-dependent factors are aimed to be
kept at 200/o f normal [7]. The desired level
is dependent on medical considerations [7.
81.
The potential application of a chromo-
genic substrate method in monitoring antivr-
tamin K treatment has been discussed ever
since the introduction of chromogenic sub-
slrates in the fieid of coagulatíon. The prob-
lem of their acceptance is no1 so much the
technical di{ïiculty of devising good spectro-
photometric tests but rather the fact that cur-
rent medical practice has defined therapeutic
Ievels of treatment in terms of overali coagu-
lation tests of the Quick type (e.g. thrombo-
plastrn time, Thrombotest) [9]. Now that sep-
arate chromogenic tests for the vitamin K-
dependent factors are available the problem
arises which factor is to be preferred and to
which level this factor should be reduced to
produce a therapeutic lowering of thrombin-
forming capacity, without introducing bleed-
ing risks.
In a large trial (n = 2,222), van Wijk [10]
observed an acceptable correlation between
l/Thrombotest values and factor X chromo-
genic activit1' (r = 0.78). The therapeutic
range for Thrombotest was taken between 5
anó 12.50/0. the corresponding therapeutlc
range for factor X chromogenic activity was
1 80-300 U/l ( I 8-30 0/o) ll ll. Poller et al' [ 1 2]
observed a good agreement between
l/Thrombotesl and factor Vll chromogenic
activit)' in plasma; percentage agreement in
diagnosis was 87.50/o'
Until now in most experimentai studies
the chromogenic activity of only one of the
vitamin K-dependent clotting factors has
been compared to Thrombotest values [10-
I 3l or to the clotting activity of the other
vitamin K-dependenl factors [10-15]' In the
present study the chromogenic activity of all
four vitamin K-dependent factors was as-
sayed in heaithy human subjects and in pa-
tients receiving oral anticoagulant drugs. The
chromogenic activities of the vitamin K-
dependent factors were correiated borh
among each other and *'ith 1,/Thrombotest'
Based on these resuits we will discuss the sutt-
abilit-v of the different assa)'s to monitor oral
anticoagulant theraPl'.
The Determination of clotting Factors with chromogenic substrates
I\'Iaterials and Methods
:\l aterials
llenous blood samples were collected in plastic
tubes containing as anticoagulant one volume triso-
dium citrate (0. l2 mol/ l)  per nine volumes of blood'
Plasma '*'as prepared b1'centrifuging the blood sam-
ples at 2.000 g for l0 min at room temperature and at
14,000g for i5 min (4 "C) to obtain platelet-poor
plasma. Plasma samples were divided into 5 po(ions
and l rozen a t  -70 'C.
Re-ference pool plasma (normal piasma) was pre-
pared b-v pooling platelet-poor plasma samples from
40 subjectively healthy subjects (20 men, 20 women)'
The plasma was frozen at -70'C in small  al iquots
conuining 0.5 ml of the reference pool plasma. During
rhe complete study rhe same reference pool plasma
was used as an internal standard to corfecl for day-
to-dal variattons.
The chromogenic substate 52337 (Bz-Ile-Glu (pi-
peridyi)-Gly-Arg-pNA) was obtained lrom Kabi AB,
Stockholm, Sweden. For the factor IX assay one vial
(conraining 24 mg lyophilized subsrate) was dissolved
in l2 ml of sterilized distilied water (2.5 mmol/l)' For
the lactor VII and X chromogenic assays one vial was
dissolved in 20 ml of sterilized distilled water
í1 .5  mmol / l ) .
.4lbumin chicken egg (ovalbumin) crystallized and
lyophilized salt-free grade V, electrophoretic purity
999b. Sigma No. A-5503.
Factor lX-deficienÍ plasma was obtained from a
palient with hemophilia B, (factor IX clotting activiry
< I olo).
Factor Vll-defcient plasma was obtained from
bovine plasma treated with diisoprop-vi-phosphoro-
f luoridate (DFP) [16].
Tissue thromboplastin was prepared from human
brain as described by Owen ll7).
Phospholipíds: Brain phosphatidylserine was pre-
pared as described by Sanders Ii8]. Egg-,volk phospha-
t idl lchol ine was obtained from Sigma (No. P86a0l.
PTT reagent for the factor IX clotring assay was
obtained lrom Roche (An. No.0740152). This re-
agent contains a brain extract serving as a thrombo-
c,vte substitute and takes care of compleïe activation of
factor XII (Hageman factor) and can be used Ío mea-
sure a decreased activity'' of the inrnnsic system.
Procedu res
Throntbotest (N,vegaard & Co., Oslo, Norway) was
performed according to Ow,ren [9].  The therapeutic
range:179-192 s, e.9., between 5 and 12.50/0. Plasmas
from patients who just started therapy or were with-
drawn from therapy were excluded from the study.
Proteins: Bovine factor X was prepared according
to Fujikawa et a1. [9]. The factor X preparations were
homogenous and pure as determined by gel electro'
phoresis in the presence of sodium dodecll sulfate
(SDS). The specific activities ofthese preparations, as
determined with a clorting assa). \r'ere equal to those
reported by Fujikawa et al. [19].
Bovine contact product was prepared according to
Nossel l20l and further purified b1' heparin-agarose
aÍlinity chromatography' as suggested by- Osterud and
Rapaport [21]. Contact producl u'as applied to the
heparin-agarose column (1.5 X 15 cm) in a buÍIer con'
taining 0.05 M sodium acelate and 0.3 M NaCl at pH
5.5 eluted with a linear gradient of 0.3-1.0 MNaCI in
A.05 M sodium acetate at pH 5.5.
Phospholipid wsicle preparatlon: Single bilayer
vesicle solutions of a mixture of brain phosphatidyl-
serine and egg-yolk phosphatidi'lcholine (25175 w/w)
were prepared according to De KruijJf et al. [22] by
sonication for 10 min in 50 nr-4r' Tris-HCl, 175 mM
NaCl at pH 7.9. Sonication was performed using a
MSE Mark II I 50 W ultrasonic disintegrator set at l0'
pm peak-to-peak amplitude. After sonication no pH
adjustment was needed.
Spectrophotomeíric assay for -factor 11.' A test kit
commercially available from Boehringer, Mannheim,
FRG, was used. In this assay the prothrombin present
in a plasma sample is quantitativel.v converted to
thrombin by a complex of factors Xa, Va, phospholip-
ids and calcium. After activation of prothrombin the
amount of thrombin present is determined with the
chromogenic substrate chromozym TH.
Spectrophot ometric assq) íor .fact or X ; A commer'
cially available test kit was used (I(abi AB, Stockholm,
Sweden). In this assay, factor X in a plasma sample is
quantitatively converted to factor Xa with the factor
X-activating enzyme from Russell's viper venom. The
amount of factor Xa formed is determined with
52337. a chromogenic peptide substrate specific for
factor Xa.
Spectrophotometric assay for -factor IX: The assay
first described b-v Tans et al. [23] was used. The assay
involves the fol lowing steps: ( l)  conversion of plasma
factor IX to factor IXa b; purified factor Xla (conuct
product): (2) incubation of factor IXa with factor X,
phospholipids and Ca2*: (3) addit ion of EDTA to stop
of factor Xa formation bv IXa: (4) determinarion of
l
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factor Xa present from rhe rare ofhydrolysis of52337:
(5) calcularion of the amount of factor Xa present.
using a calibration cun'e made u'ith reference pool
plasma.
Since the Uvicon 810 (Kontron) spectrophotome-
ter used in our studies is not as sensit ive as the
Aminco DW2 used b1' fans et al. [23] it was necessar]'
to modifl the procedure such that higher absorbance
changes were obuined. The details of the method are
as follou s: in the first step 90 pl buffer with ovalbumin
(175 m.11 NaCl, 50 m'1-í Tris-HCl, pH 7.9 at 25 "C,
0.5 mg ml ovalbumin). 15 pl CaClr (0. i  'e4, 15 tt l
(0.225 me) factor XIa (contact product) and 30 pl
plasma (di lut ion 1:10) incubated at 37 "C during
25 min. From this mixture 100 pl is sampled to a mix-
tuie. prewarÍned at 37 'C for 5 min. containing 200 pl
of buffer xith ovaibumin, I00 pl faclor X (1 p'14) and
100 pl Car* phospholipid mixture (500 F,t'l phospho'
lipid vesicies and 50 rn-ly' Ca2*. Faclor Xa formarion is
stopped b1' transfer of 0.4 ml sample to a cuvette con-
taining 0.55 ml of bu{ïer with ovalbumin, containing
20 m][ EDTA.
Finaill . 50 pl 52337 (2.5 m:lí) is added and the
change in absorbance at 405 nm is measured' The
amount of factor IX in the plasma sample is read from
a calibration cun'e made wirh varling amounls of lhe
reference pool plasma (fig' 1). A neu' teference curye
was made each time the assay was used in order to
correct for day-to-da.v variations. All measurements
were corrected for a reagent blank (ÀAa05/min ob-
ained without Plasma).
Spectrophotometric assal' for ;factor WI: The pro-
cedure first described by Seligsohn et al. [13] was used,
modified as follows: in a first step the plasma sample
(40 pl. dilution 1:100). containing factor VII, was in-
cubated '*'ith tissue thromboplastin (10p1). CaCl2
0.1 lí (20 til), buffer wirh ovalbumin as described for
the lacror iX assa-v (l l0 pl) and a trace of factor Xa
(l n-\[, 20 Él) to allo*' quantiative conversion of fac'
tor VII to lactor VIIa (5 min at 37'C). Hereafter the
factor X activation reaction was sbned by the addt-
tion of factor X (10 u-11, 10 pl). After 4 min of factor
Xa iormation the reaction is stopped by addition of
buffer *'tth ovalbumin. conraining 20 rn-\'l EDTA
(0.? ml). in the last step. factor Xa activi t-v is mea-
sured b) adding 0.1 ml 52337 (1.5 nrMl and determin-
' ing the init ial  rate ofcleavage ofthis chromogenic sub-
strare. The amount of factor VII act ivi t l '  gas read
from a cal ibrat ion cun e ofthe reference pool plasma'
A neu cal ibrat ion cun e gas made each t ime the assa)'
was used. Due to the presence of a trace of factor Xa in
the preincubation reaction no lag period in the facror
Xa formation as reported by Seligsohn et ai' [13] was
observed. Another difference is that bovine factor X
rather than human factor X is used in our assay' The
concentration of factor X in the assay is 0'41 p'M'
equal to three times the plasma factor X concentra-
tion. In contrast to the results of Seligsahn et al' [13]
wilh human factor X, we found lou blank values in
the absence of plasma (reagent blank)' The teagent
blank was 0.001 AA405/min, thar is about 1.5 0/o ofthe
ÁA405/min found for the reference pool plasma (ta-
ble Ii). All measurements were corrected for this re'
agent blank.
Factor VII cloning 4ss4-v was performed according
ro Nemerson and ClynP ll$1.
Factor IX clottíng assay:0'l ml factor IX-deficient
plasma,0.1 ml test patient plasma (t:10 di iut ion) and
0.1mI PTT reagent from Roche were incubated at
37'C for 5 min. Hereafter 0.025 M Ca2* was added
and the clotting time was measured [24].
Statistical analysis of the data: The signiÍicance of
differences between two values was tested by a paired
Student's t test [25]. Rank coeÍïicients of correlation
were calculated according to the method of Jonge 125)
and Spearman [26]. The rank coeÍïicient ofcorreiation
is a distribution-free, nonparamelric coeÍïicient of cor-
relation.
Results
Analytical Variables
The linearítt, of the assa.vs:The linearity of
the different chromogenic assays was investi-
gated by testing dilutions of the reference
pool plasma and of a patient receiving oral
anticoagulant therapy. Figure I demonstrates
the results for factor IX.
Within- and Between-'4ssay Precísion of
the different assays is shown in table i. With-
in-assay precision was eslimated by assaving
two dilutions of the reference pool plasma
(100 and 250/o) 10 times each. Variations are
expressed as a percentage of the mean activ-
itf in plasma. Between-assa-v precision of the
chromogenic assays was delermined by use
rïe,rjs"11qii ffi rrryÊq*@yr*T.rf-F.f ff ËïÏ
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Fig. l. Calibration curve ofthe factor IX chromogenic assay. Different dilutions ofthe reference pooi piasma
(r). DiÍïerent dilurions of plasma from a patient receiving oral anticoagulants 1o).
Table I. Within- and between-assay precision of vanous assays
{ssa!' Within-assav variation. o/o Between-assay
variation, oÁ
100% RPl00o/o RP 250lo RPr
Factor II chromogenic activity
Factor X chromogenic activitl'
Factor IX chromogenic activily
Factor IX clotring acÍivity
Factor Vl l  chromogenic activi ty
Factor VII clorting activity
Thromborest:
3 .6
3.0
5 . 1
13 .0
3 .5
) . 1
7.4 (40olo RP)
5.4
{ . J
6 .7
5.6
J .  I
3.8 (250/o RP)
6.0
5.0
8.8
5 .8
,., (rroroor)
CoeÍIcient ofvariation: standard devialion as a percentage ofthe mean.
\\'ithin-assa-v-. r'ariation: coeÍllcient of variation for chromogenic measuremenls on the same day.
Bet*sg11-3552;' variation: coeÍIicient of variation for chromogenic measurements on diÍIerent days.
RP = reference pool plasma. obtained from 40 subjectively healthy donors (20 men, 20 women).
Thrombotest is insensit ive to values lareer than 30-40%.
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Table II. Variation in normal values
Assar: Mean
o/o RP
Mean
Aa65lmin
CV,ot
o/o
CVu;otl
o/o
Factor II chromogenic assay
Faclor X chromogenic assa1,
Factor IX chromogenic assav
Factor IX clotting assa;.
Factor VII chromogenic assay
Factor VII clottine assav
J J "
32b
J J '
14c
J J "
14c
10  i . 4
r  06.9
98.2
94.0
99 .3
107.4
0.2468
u . t o l
0.028
0.0645
t2.2
r  5 .0
1 1 . 0
t6.4
2t.4
2  r . 8
t t .7
14 .8
9 .7
10.0
2 t . 2
21.2
n = N u m b e r o f d o n o r s : a = 2 1 m e n a n d  l 2 w o m e n ;  b = 2 1 m e n a n d  l l  w o m e n .  I o u t i i e r ( p < 0 . 0 1 ) ; c = 7 m e n
and 7 women (RP, see rable I).
I CV,o,2 = CVassr-i + CV6io12. CV = s6sffraiant of variation expressed as a percentage of mean.
Table III. Mean values for 98 coumarin-treated patients
Assa_v No assays Mean
o/oRP
Range
o/o RP
Therapeutic o/o agreement
range with TTr
Factor II chromogenic assay
Factor X chromogenic assay
Factor IX chromogenic assay
Factor VII chromogenic assay
Thrombotest
98
98
oe
98
98
? a ?
3 1 . 1
41.7
45.0
10.4
tI.3-70.2
18.5-ó8.9
r 9.6-96.3
15.6-80.3
5.È25.0
t2.6-36.1 86.7
t8.9-36.2 89.8
23.149.3 81.6
27.o-s2.3 78.6
5.0-12.5
I In comparing two diÍïerent tests. results were divided into three calegories: therapeutic. underdosed and
overdosed. The percentage agreement between Thrombotest and a chromogenic assay represents the percenuge
ofcases in which the two different tests result in the same diagnosis with relation to oral anticoagulant therapy.
(RP, see table I).
of the reference pool plasma, stored in small
portions al -70 "C. On l0 subsequent days
one portion was assayed, from which the
between-assay variarion could be calculated.
Clinícal Results
l/aríaíion in normal values: We assayed
factor II. VII, IX and X chromogenic activi-
t ies in 33 healthi '  volunteers (21men, i2
women). The total variation (rnterindividual
variarion) and the biological variation ofthe
normal values are presented in table II. Espe-
cially for factor IX a rather small biological
variation (less than 100/o) is observed. For the
factors IX and VII clotting activity was also
assayed in 14 normal plasmas (7 men, 7
women). Especially for factor IX a much
larger variation in the clotting activity (ex-
pressed as a percentage of the same reference
pool as used in the chromogenic assay) is
observed compared to results obtained with
the spectrophotometric method (table II).
Comparison o-f chromogenr, orrit'i1y of vi-
tamin K-dependenÍ 
.factors and Thrombolesí
_ 1.a\'""YY1-',:=-*:.4*.*.*...
-.:! * !* f;
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"íable I\'. Correlation beÍween the various chromogenic assays and Thrombotest (fi)
98 coumarin-treated Datientsr I 0 I coumarin-treated patients
and 33 normal personsz
rR\ ss3 \  s
'fï r s. làctor II
TT ls. lactor X
-lT r s. Íaclor IX
' lT r s. lactor VII
i : i i tor i l  vs. factor X
Factor I i  vs. factor IX
Facror l l  vs. factor VII
iactor IX vs. factor X
Factor lX vs. factor VII
Factor .\ r's. factor. VII
0.88
0 .78
0.'72
0.72
0 .7  8
0.64
0.ó5
u .0  /
0.70
0.5 5
0.83<0.88<0.92
0.77 <0.84<0.89
0 .67<0 .78  <0 .85
0 .66<0 .76<0 .83
0.76 <0.83 <0.88
0 .62<0 .73<0 .81
0 .52<0 .65  <0 .75
0 .74<0 .82<0 ,88
0.58<0.70<0.79
0.47 <0.61<0.72
0.94<0.96 <0.97
0.89<0.92<0.94
0.82<0.87<0.9ó
0.89<0.92<0.94
0 .81<0 .8ó<0 .89
0 .84<0 .88<0 .91
fp: rank coefÍlcient ofcorrelation, i.e. a distriburion free (nonparametric) determination ofthe coeÍIicient of
corr!'lal j on [cf . 25, 26].
;': coeÍïcient of correlation; the 950/o confidence limits are also given.
: n = 98: 75 men and 23 women.
: n = 134: 98 men and 36 women.
t'alttes in 98 patients on long-term anticoagu'
iunt therap-v-:From the De Wever Hospital in
Hecrien we chose 98 patients receiving long-
terrn oral anticoagulant reatment (75 men,
33 *'omen) and compared the Thrombotest
values ro results obtained with the four dif-
ferent spectrophotometric methods, used to
assa) the piasma activities of the four vita-
min K-dependent factors. Table III summa-
rizes the resuits and in table IV the coefïi-
cic'nts of correlation between the diíïerent
assavs are given. The 950/o confidence limits
of the coeíïlcienrs of correlation are shown.
\\'e also computed the rank coeÍïcient of cor-
relalion. a distnbution-free determination of
lhc cor-fficient of correlation. according to
. \ ; t t , t r t r :en I l6 l .  This rank coeÍïcient of  cor-
rL'lation is not influenced by the range of the
i'tlr'asurÈments. As can be seen from table III,
aci i r i t ics of the clot t ine. facrors are distr ib-
uted over different ranges. In this case a rank
coefficient of correlàtion will better reflecl
the correlation between the diíïerent assays,
compared to the normal coefïicient of corre-
lation.
Figure 2a{ shows the correlation be-
tween l/Thrombotest and the chromogenic
activity of the factors II, VII. IX and X. The
best correlation was observed between
I /Thrombotest and factor II chromogenic ac-
t iv i ty (r  = 0.88).
The'therapeutic range' is a distinct degree
of drug-induced inhibition of the coagula-
tion, which is regarded as prolecting against
thrombus formation, according to previous
clinicai experiences the range for the Throm-
botest as routineiy used in our laboratory is
between 179 and 92 s, i.e. betweèn 5 and
12.5o/o. When the therapeutic range for
Thrombolest is set between 5 and 12.50/o the
i',
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1 /THROMAOTEST ( sec - l )
Fig. 2. a-d Correlation between l/Thrombotest and factor II, vII, IX and X chromogenic activities in
patients receiving oral anticoagulant therapy.
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therapeutic ranges for the factors II, VII, IX
and X can be calculared (table iII).
Comparison of chrontogenic assays and
clotting assays: For part of the plasma sam-
ples, factor VII and factor IX plasma clotting
activiries were measured rvith clotting assays
and the results were compared to the results
oblained with the chromogenic assays. Cor-
relation u,as good between factor VII chro-
mogenic assay' and factor VIi clotting assay
(r = 0.94. fig. 3). Horvever. rhere was a signif-
icant difference bet*,een the values obtained
for both assays in this group of patients
(paired t test, p < 0.05). The factor VII clot-
ting activity was consistently lorver than the
factor VII chromogenic activity. Correlation
between factor IX chromogenic activity and
factor IX clotting activity was less good (r =
0.88, n = 38, fig.4). This is probably caused
by the insensitivity of the factor IX clotting
assay compared to the factor VII clotting
assay. There was no signiÍicant difference be-
tween the results obtained with the factor IX
clotting assay and the results obtained with
the facror IX chromogenic assay (fie. 4) (p <
0.0s).
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Discussion
Thc carboxylation of des-y-carboxy fac-
ton II. \ ' l l ,  IX or X to their biologicaliy
Jftrvc 7\'rn6gens is vitamin K dependent and
lhirs trcatment of patients with vitamin K
;ni;iqonists *' i l l  result into decreased levels of
thc carboxl' lated forms of the four vitamin
1,.-dcp,:ndent clotting factors. Thrombin-
iornring capacitr, wil l be decreased under
:hcrc cil-cumstances and this principle under-
irt-r oi:rl anticoaguiant therapy for patients
\! rlh cerdiovascular and thromboembolic
r ! : r . r1 i !  ' - . .  
. { r  present  the rout ine moni lor ing
,': '  ir lr l anticoagulant therapl' occurs with
thromboplastin time tests like Thrombotest
for example. These clotting assays invoive
the activation reactions of the extrinsic cas-
cade, resulting in the formation of a frbrin
clot. Reduction of the concentration of the
vitamin K-dependent clotting factors reduces
the rale of some of the acrivation reactions
and the cumulative effects are measured.
Since the introduction of chromogenic
peptide substrates for thrombin and factor
Xa, spectropholometric methods have been
developed to determine the activity of each
of the vitamin K-dependent ciotting factors
individually. The possible application of
chromoeenic substrates to monitor oral anti-
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coagulant therapy has been suggested ever
since [3, 11-13, 27, 28]. One of the advan-
tages of the use of chromogenic substrates to
monitor oral anticoagulant therapy is that
spectrophotometric methods can be auto-
mated, resulting in considerably smaller as-
say variations. When the automated analyzer
is interfaced with a computeÍ the results for a
test sample can be translated into a dosage by
a computer'programmed dosage scheme
l t  l l .
Presently a much discussed question is
which of the vitamin K-dependent factors
should be chosen to monitor oral anticoagu-
lant therapy. Before there can be thought of
replacing Thrombotest by a spectrophoto-
metric assay it has to be evaluated vefy care-
fully which of the four factors, if any, should
be preferred.
In table V we give several criteria that can
be used to evaluate to suitability ofthe differ-
ent chromogenic tests to monitor oral antico'
agulant therapy: (l) The assay used should be
simple; (2) The biological variation in the
normal plasma activity should be small;
(3) The biological half-life of the clotting fac-
tor should be short, because plasma activities
of clotting factors that have a short halÊlife
better reflect the momentary state of antico-
agulation of the patient; (4) It should be posst-
ble to define a zone of optimal anticoagula-
tion. Up till now rhis has been dehned in
The Determination of Clotting Factors with Chromogenic Substrates z > l
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trrms of Thrombotest values. This. however.
r\ an overall test and it is actually unknown
'.rhich factor(s) is (are) responsible for thera-
t",'utic cffbcts and bleeding risk. Therefore,
t;nall; a large prospective double-blind study
lir cs11',0"r. the results obtained with the best
ehromogenic assay and the conventional
ïhromborest should be performed.
i,i,.r.t l'uriatiort and Simplicíty of the
i \.Í.1_l'
ïhc chromogenic assays for factors II and
\ :x15111.- onll'a few pipetting steps and can
"' 
,;i. 'mplclL'd u'ithin 5 min. In contrast the
,,..-:' ' for tactor IX in its present form re_
'::s iri ' lg incubation times. Further re-
search could lead to simplification of this
assay. Inclusion of factor VIIIa in the assay
would shorten the assay time, because it
stimuiates the rate of factor X activation and
therefore measurabie amounts of factor Xa
would be produced faster. The larger assay
variation for factor IX (table I), compared to
assay variations of 3-3.50/o for the factors II,
VII and X may be a consequence of the fact
that the faclor IX assay requires longer in-
cubation times and produces smaller ab*
sorbance changes than the other assays.
Automation of the assa1, could reduce this
variation. Automation of the factor X as-
say reduced the assay variation from 3.5 to
1 .90 lo  [0 ] .
ffi
É 1 1
iil
l ! l
i ' l
; i l
t 1 i
lil
:rl
i r ,
ri!
li!
t liil
;;ií t
: t
i l
l l
il
i,llit
ill
iil
i lli
' lliil
rtl
ill
;ii
i i l! , r
j , l
' r !
u
U
siry
van Dieijen-Visser/van Wersch/Brombacher/Rosing/Hemker/van Dieijen
y : . 9 1 7 r  +  3 . 4
n= 3{l
r  =  0 .88
I
o
o
o
Èf
=
F
z
F
F
I
o
o 20 40 60 80 100 120 140
FACTOÊ tX CHFOMOGENIC aCTlv l ïY  (% o t íe Íè rence p lesmal
Fig.3. Conelation between factor IX clotting assay and factor IX chromogenic assay for factor IX activity iD
healthy subjects (n = 14) and in patients receiving oral anticoagulants (n = 24).
Table V. Criteria to evaluate the suitability of diÍIerent chromogenic assays to monitor oral anticoagulant
theÍapy
Assay Assay Simplicity
variation, o/o of the assayl
Biological Relation
variation, % to TT, rp
Biological
halflife, h
Factor II chromogenic assay
Factor X chromogenic assay
Facror IX chromogenic assay
Factor VII chromogenic assay
Thrombotest
3.6
J . U
5 . 1
3 .5
3 .8
I
J
5
I
48-9ó
4H0
I 8-30
:
11.7
14.8
,:'
0 .88
0.78
4.72
0.'12
Ideal assay: one-step; small assay variation; shoí
I Simplicity ofthe assays is graded on a scale from I
5 is a more complicated and lime-consuming assay.
biological half-life; small biological variation.
!o 5. u'here I can be carried out fast in a few steps, whereas
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An advantage of ïhrombotest remains
thal ir can be carried out in whole blood
u hcreas plasma is needed in the chromogenic
ass.rvs. Therefore, Thrombotest is especially
surtable in urgent situations, since one tesl
can be performed within 2 min. Although
clotring assays can be mechanized, which À_qurrcs spccial apparatus, chromogenic assays
can i^* implemented on automated spectro_photomerers already present in the ctinlcat
hiroraton'.
I i : ,  . : t ,{ t t  al  l .ar iat ion
I i ,r ir iological variations in the activitv in
,".:":'r:r of the factors X and VII, measured
with chromogenic assays and estimated from
the activity in plasma of 33 healthy subjecrs,
show great similarities with results obtained
by van.Wijk et al. [l l] for facror X and by
Seligsohn et al. Il3J for factor VII. The activ-
ity of the factors II and IX in 'normal' plas-
ma, measured with a chromogenic assay are
published here for the hrst rime. For factor
IX the smallest biological variation is found
(less than l0 0/o) and the largest biotogical
varialion is found for factor VII (about 22o/o).
Choice of a facror (like iX) with a small bio-
logical variation is. preferable since a reduc-
tion in activity of that facror (as a result of
: anlicoagulant therapy), more accucttely re-
flects a change in slnthesis rate.
:!i!. i
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Biological Half-Lifc
Due to the short half-iife of disappearance
of factor VII (as measured after the adminis-
tration of a blocking dose of anticoagulant)
and of reappearance (as measured after the
subsequent administration of vitamin K) fac-
tor ViI levels in plasma are the hrst to be
lowered after beginning of anticoagulant
therap-v. However, the large biological vana-
tion of facror VII activil)' in plasma makes
this factor less suitable to monitor patients
receiving oral anticoagulants. Therefore. fac-
tor IX u'ith a half-life somewhat larger than
factor VII should be preferred because it also
has the lowest biological variation (< i00/o).
Moreover. on the general principle that the
frequency at which the patients should be
con{rolled must be of the order of magnitude
of the halÊlife of the phenomenon to be
observed, factor VII can be excluded as a
suitable candidate to monitor oral anticoagu-
iant therapy. According to this principie. fac-
tors II and X are not suitable to monitor
patients receiving oral anticoagulants for
only a short period of time lHemker and van
Dam-Mieras, unpublished resuitsl. The coef-
ficient of correlation that we found between
the reciprocal of Thrombotest and factor X
chromogenic activity is comparable with that
reported by Bergstrcim and Egberg [28] and
by van Wijk et al. [ 1]. The therapeutic range
for Thrombotest also compares well with rhe
results obtained by van I'l"ijk et ai. [11].
PolLer et al. [i2] obsen'ed a percentage
agreement in diagnosis. assessed $'ith
Thrombotest and factor VII chromogenic ac-
tivity of 87.5o/o in patients receiving long-
term anticoagulant therap-v.
Treatment with vitamin K antagonists re-
sults in the appearance of partl-v carboxy'lated
lactor II, \/Ii. iX and X molecules in the cir-
cuiation. Partlv carborvlaled molecules mav
account for the significanl differences in
piasma activities measured with a clotting
assay or u,ith a chromogenic assay, as ob-
served for factor X b1, r'an l4tijk et al. [11].
and for factor VIi br- Selíghsohn et al. [13]
and in this study. However. the difference we
observed bet*'een factor VII clotting activity
and factor VII chromogenic activity is much
less than that observed by Se&gsohn et al.
[13]. For factor IX we found no significanr
difference between activities measured with a
clotling test or with a chromogenic assay.
We conclude that factor II bilt also the fac-
tor X chromogenic activity in plasma can be
used to monitor patients receiving long-term
anticoagulant therap-v, whereas factor IX
chromogenic activit,v should be preferred to
monitor parients receiving oral anticoagu-
iants during a short period of time.
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